Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

High miR-34a and miR-26b expressions inhibit prostate cancer cell OPCN-1 proliferation and enhances apoptosis

Yingwei Lin¹, Tao Sun², Guoliang Sun²

¹Department of Laboratory Medicine, The Second Affiliated Hospital of Dalian Medical University, Dalian, Laizhou, China; ²Department of Urology, Laizhou People's Hospital, Laizhou, China.

For correspondence:- Guoliang Sun Email: sglxjyycx@sina.com Tel:+8618561084757

Accepted: 19 January 2022 Published: 28 February 2022

Citation: Lin Y, Sun T, Sun G. High miR-34a and miR-26b expressions inhibit prostate cancer cell OPCN-1 proliferation and enhances apoptosis. Trop J Pharm Res 2022; 21(2):229-236 doi: 10.4314/tjpr.v21i2.3

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effects of miR-34a and miR-26b on the targeted genes, LEF1 and EphA2, and proliferation and apoptosis of OPCN-1.

Methods: Sixty specimens of cancer tissue (CT) and equivalent tissue adjacent to tumors (TAT) were collected from prostate cancer patients. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to determine the mRNA expression levels of miR-34a, miR-26b, LEF1, and EphA2 in the above tissues, while protein expression levels of LEF1 and EphA2 were evaluated by Western blot.

Results: Compared with TAT, the expression levels of miR-26b and miR-34a in CT decreased significantly (p < 0.05), whereas the mRNA and protein expression levels of EphA2 and LEF1 in CT significantly increased (p < 0.05). TargetScanHuman7.2 assay data revealed that miR-26b targeted EphA2, while miR-34a targeted LEF1. MiR-26b MG showed decreased EphA2 mRNA and protein levels when compared with miR-26b-NC group after overexpression. The miR-34a MG exhibited decreased expression levels of LEF1 mRNA and protein compared with the miR-34a-NC group. Between 48 and 72 h, miR-26b MG grew more slowly than miR-26b-NC group; miR-34a MG also showed significantly slower growth than miR-34a-NC group. The miR-26b MG and miR-34a MG groups displayed higher apoptosis rate than miR-26b-NC and miR-34a-NC groups, respectively.

Conclusion: High expressions of miR-34a and miR-26b targeted the inhibition of LEF1 and EphA2, respectively, indicating that they inhibit the proliferation, and also control the increased apoptosis rate of OPCN-1 cells. Hence, miR-34a and miR-26b are probable molecular targets for the development of new prostate cancer drugs.

Keywords: Prostate, miR-34a miR-26b, LEF1, EphA2